
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY
I Background Information:
A 510(k) Number
K211485
B Applicant
Diagnostica Stago SAS
C Proprietary and Established Names
STA - NeoPTimal
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 864.7750 -
GJS Class II HE - Hematology
Prothrombin Time Test
II Submission/Device Overview:
A Purpose for Submission:
New Device
B Measurand:
Prothrombin Time (PT) in seconds and International Normalized Ratio (INR)
C Type of Test:
Quantitative
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
www.fda.gov

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
GJS			Class II	21 CFR 864.7750 -
Prothrombin Time Test			HE - Hematology

--- Page 2 ---
B Indication(s) for Use:
The STA - NeoPTimal kits provide thromboplastin reagents from rabbit brain extract, for the
quantitative determination, in human citrated plasma (3.2% sodium citrate), of Prothrombin
Time (PT) on STA-R family, STA Compact family and STA Satellite family instruments. STA -
NeoPTimal is a coagulation screening test intended to be used by professional laboratory
personnel for the evaluation of the extrinsic coagulation pathway and the monitoring of oral
vitamin K antagonist therapy using the International Normalized Ratio (INR).
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
STA-R family includes STA-R (K983460), STA-R Evolution (K093001) and STA R Max
(K151867).
STA Compact family contains STA Compact (K093167) and STA Compact Max (K130090).
STA Satellite family contains STA Satellite (K082248).
IV Device/System Characteristics:
A Device Description:
The in vitro diagnostic STA - NeoPTimal kits are available in two sizes and contain:
STA - NeoPTimal 5 STA - NeoPTimal 10
6 x 5 ml vials of Reagent 1 12 x 10 ml vials of Reagent 1
6 x 5 ml vials of Reagent 2 12 x 10 ml vials of Reagent 2
Reagent 1 in STA - NeoPTimal is lyophilized thromboplastin prepared from rabbit brain extract.
The STA - NeoPTimal reagent contains a specific heparin inhibitor. Reagent 2 is a solvent
containing calcium.
B Principle of Operation:
The STA - NeoPTimal, an in vitro diagnostic test consists of the use of calcium thromboplastin
to measure the clotting time (formation of a fibrin clot) of the patient’s plasma and to compare it
with that of a normal standard (MNPT). The test measures, as a whole, the activities of the
coagulation factor II (prothrombin), factor V (proaccelerin), factor VII (proconvertin), factor X
(Stuart factor) and factor I (fibrinogen).
V Substantial Equivalence Information:
A Predicate Device Name(s):
Thromborel S
B Predicate 510(k) Number(s):
K211485 - Page 2 of 13

[Table 1 on page 2]
	STA - NeoPTimal 5			STA - NeoPTimal 10	
6 x 5 ml vials of Reagent 1			12 x 10 ml vials of Reagent 1		
6 x 5 ml vials of Reagent 2			12 x 10 ml vials of Reagent 2		

--- Page 3 ---
K003870
C Comparison with Predicate(s):
Device & Predicate
K211485 K003870
Device(s):
Device Trade Name STA - NeoPTimal Thromborel S
General Device
Characteristic Similarities
The STA®- NeoPTimal
kits provide
thromboplastin reagents
from rabbit brain
extract, for the
quantitative
determination, in
human citrated plasma
(3.2% sodium citrate),
Thromborel S Reagent
of Prothrombin Time
is used for the
(PT) on STA-
determination of the
R®family, STA
Prothrombin Time (PT)
Compact® family and
STA Satellite® family according to Quick and,
Intended Use/Indications
instruments. STA®- in conjunction with
For Use
NeoPTimal is a the relevant deficient
coagulation screening plasmas, for the
test intended to be used
determination of the
by professional
coagulation factor II,
laboratory personnel for
V, VII and X.
the evaluation of the
extrinsic coagulation
pathway and the
monitoring of oral
vitamin K antagonist
therapy using the
International
Normalized Ratio
(INR).
Assay Method Clotting Time Same
The STA - NeoPTimal The Thromborel S test
test consists of the is a coagulation
use of calcium process triggered by
Test Principle thromboplastin to incubation of plasma
measure with thromboplastin and
the clotting time of the calcium. The time
patient’s plasma and to formation of a fibrin
K211485 - Page 3 of 13

[Table 1 on page 3]
	Device & Predicate		K211485	K003870
	Device(s):			
Device Trade Name			STA - NeoPTimal	Thromborel S
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			The STA®- NeoPTimal
kits provide
thromboplastin reagents
from rabbit brain
extract, for the
quantitative
determination, in
human citrated plasma
(3.2% sodium citrate),
of Prothrombin Time
(PT) on STA-
R®family, STA
Compact® family and
STA Satellite® family
instruments. STA®-
NeoPTimal is a
coagulation screening
test intended to be used
by professional
laboratory personnel for
the evaluation of the
extrinsic coagulation
pathway and the
monitoring of oral
vitamin K antagonist
therapy using the
International
Normalized Ratio
(INR).	Thromborel S Reagent
is used for the
determination of the
Prothrombin Time (PT)
according to Quick and,
in conjunction with
the relevant deficient
plasmas, for the
determination of the
coagulation factor II,
V, VII and X.
Assay Method			Clotting Time	Same
Test Principle			The STA - NeoPTimal
test consists of the
use of calcium
thromboplastin to
measure
the clotting time of the
patient’s plasma and	The Thromborel S test
is a coagulation
process triggered by
incubation of plasma
with thromboplastin and
calcium. The time
to formation of a fibrin

--- Page 4 ---
to compare it with that clot is then
of a normal standard. measured.
The test measures, as a
whole, the activity of
the coagulation factor II
(prothrombin),
factor V (proaccelerin),
factor VII
(proconvertin), factor X
(Stuart factor) and
factor I (fibrinogen).
General Device
Characteristic Differences
Thromboplastin source Rabbit brain Human placenta
STA-R Family, STA
Sysmex CA series and
Analyzers Compact Family and
Siemens BCS series
STA Satellite Family
VI Standards/Guidance Documents Referenced:
• CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures;
Approved Guideline – Third Edition
• CLSI H47-A2: One-Stage Prothrombin Time (PT) Test and Activated Partial
Thromboplastin Time (aPTT) Test; Approved Guideline – Second Edition
• CLSI H48: Determination of Coagulation Factor Activities Using the One-Stage Clotting
Assay; 2nd Edition
• CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement
Procedures; Approved Guideline – Second Edition
• CLSI EP07: Interference Testing in Clinical Chemistry; 3rd Edition
• CLSI EP25-A: Evaluation of Stability of In Vitro Diagnostic Reagents; Approved
Guideline
• CLSI EP28-A3c: Defining, Establishing and Verifying Reference Intervals in the Clinical
Laboratory; Approved Guideline – Third Edition
• CLSI H21-A5: Collection, Transport, and Processing of Blood Specimens for Testing
Plasma- Based Coagulation Assays and Molecular Hemostasis Assays; Approved
Guideline – Fifth Edition
• CLSI H54-A: Procedures for Validation of INR and Local Calibration of PT-INR
Systems; Approved Guideline – First Edition
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
K211485 - Page 4 of 13

[Table 1 on page 4]
			to compare it with that
of a normal standard.
The test measures, as a
whole, the activity of
the coagulation factor II
(prothrombin),
factor V (proaccelerin),
factor VII
(proconvertin), factor X
(Stuart factor) and
factor I (fibrinogen).	clot is then
measured.
	General Device			
	Characteristic Differences			
Thromboplastin source			Rabbit brain	Human placenta
Analyzers			STA-R Family, STA
Compact Family and
STA Satellite Family	Sysmex CA series and
Siemens BCS series

--- Page 5 ---
Repeatability was assessed with three lots of STA - NeoPTimal on a representative of each
analyzer family: STA-R, STA Compact and STA Satellite. The study was conducted using
four lots of reagents at one external site. The study was conducted for 20 days with two runs
per day and two replicates per run by two operators. The STA - NeoPTimal test demonstrated
acceptable repeatability when evaluated using control materials and 3.2% citrated plasma
patient samples. The repeatability results for a representative of each analyzer family for PT
in seconds and INR are summarized below.
Repeatability on STA-R, PT in seconds
All Lots (seconds) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 240 14.270 0.119 0.83 0.140 0.98 0.201 0.57 0.000 0.00 0.201 1.41
Normal 2 240 13.861 0.126 0.91 0.132 0.95 0.210 0.75 0.000 0.00 0.210 1.52
VKA
240 30.888 0.341 1.10 0.700 2.27 0.838 1.00 0.248 0.80 0.838 2.71
2≤INR≤3
VKA
240 45.502 0.416 0.91 0.951 2.09 1.038 0.00 0.364 0.80 1.038 2.28
3<INR≤4
VKA
240 62.892 0.527 0.84 1.413 2.25 1.594 0.82 0.471 0.75 1.594 2.53
4.5<INR≤5.5
VKA> 5.5 240 70.665 0.783 1.11 2.062 2.92 2.206 0.00 0.456 0.65 2.206 3.12
Def V 240 26.270 0.339 1.29 0.520 1.98 0.621 0.00 0.190 0.72 0.621 2.36
*SCN 240 14.831 0.138 0.93 0.138 0.93 0.202 0.35 0.028 0.19 0.202 1.36
*SCP 240 26.111 0.256 0.98 0.656 2.51 0.712 0.41 0.000 0.00 0.712 2.73
^CCN+ 240 14.908 0.125 0.84 0.184 1.23 0.222 0.00 0.000 0.00 0.222 1.49
^CCABN+ 240 38.953 0.307 0.79 1.056 2.71 1.100 0.00 0.000 0.00 1.100 2.82
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Repeatability on STA-R, INR
All Lots (INR) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 240 1.042 0.010 0.96 0.010 0.96 0.015 0.58 0.014 1.34 0.015 1.47
Normal 2 240 1.012 0.009 0.89 0.010 0.99 0.015 0.69 0.015 1.48 0.015 1.50
VKA
240 2.317 0.027 1.17 0.054 2.33 0.065 0.99 0.050 2.16 0.065 2.79
2≤INR≤3
VKA
240 3.458 0.032 0.93 0.075 2.17 0.082 0.00 0.095 2.75 0.082 2.36
3<INR≤
VKA
240 4.832 0.042 0.87 0.114 2.36 0.128 0.83 0.151 3.13 0.128 2.65
4.5<INR≤5.5
VKA> 5.5 240 5.451 0.062 1.14 0.164 3.01 0.175 0.00 0.170 3.12 0.175 3.22
^CCN+ 240 1.091 0.010 0.92 0.014 1.28 0.017 0.00 0.016 1.47 0.017 1.58
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Repeatability on STA Compact Max, PT in seconds
All Lots (seconds) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 240 14.401 0.191 1.33 0.159 1.10 0.260 0.52 0.000 0.00 0.260 1.80
Normal 2 240 14.132 0.209 1.48 0.246 1.74 0.353 1.00 0.000 0.00 0.353 2.50
VKA
240 29.531 0.589 1.99 1.053 3.57 1.207 0.00 0.136 0.46
2≤INR≤3 1.207 4.09
VKA 240 44.070 0.870 1.97 1.635 3.71 1.852 0.00 0.478 1.08 1.852 4.20
K211485 - Page 5 of 13

[Table 1 on page 5]
	All Lots (seconds)					Repeatability						Between-run						Between-day						Between-lot						Within-lab				
	Sample	N			Mean	SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV	
Normal 1		240		14.270		0.119		0.83			0.140			0.98			0.201			0.57			0.000			0.00			0.201			1.41		
Normal 2		240		13.861		0.126		0.91			0.132			0.95			0.210			0.75			0.000			0.00			0.210			1.52		
VKA
2≤INR≤3		240		30.888		0.341		1.10			0.700			2.27			0.838			1.00			0.248			0.80			0.838			2.71		
VKA
3<INR≤4		240		45.502		0.416		0.91			0.951			2.09			1.038			0.00			0.364			0.80			1.038			2.28		
VKA
4.5<INR≤5.5		240		62.892		0.527		0.84			1.413			2.25			1.594			0.82			0.471			0.75			1.594			2.53		
VKA> 5.5		240		70.665		0.783		1.11			2.062			2.92			2.206			0.00			0.456			0.65			2.206			3.12		
Def V		240		26.270		0.339		1.29			0.520			1.98			0.621			0.00			0.190			0.72			0.621			2.36		
*SCN		240		14.831		0.138		0.93			0.138			0.93			0.202			0.35			0.028			0.19			0.202			1.36		
*SCP		240		26.111		0.256		0.98			0.656			2.51			0.712			0.41			0.000			0.00			0.712			2.73		
^CCN+		240		14.908		0.125		0.84			0.184			1.23			0.222			0.00			0.000			0.00			0.222			1.49		
^CCABN+		240		38.953		0.307		0.79			1.056			2.71			1.100			0.00			0.000			0.00			1.100			2.82		

[Table 2 on page 5]
	All Lots (INR)							Repeatability						Between-run						Between-day						Between-lot						Within-lab				
	Sample	N			Mea	n		SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV	
Normal 1		240		1.042			0.010			0.96			0.010			0.96			0.015			0.58			0.014			1.34			0.015			1.47		
Normal 2		240		1.012			0.009			0.89			0.010			0.99			0.015			0.69			0.015			1.48			0.015			1.50		
VKA
2≤INR≤3		240		2.317			0.027			1.17			0.054			2.33			0.065			0.99			0.050			2.16			0.065			2.79		
VKA
3<INR≤		240		3.458			0.032			0.93			0.075			2.17			0.082			0.00			0.095			2.75			0.082			2.36		
VKA
4.5<INR≤5.5		240		4.832			0.042			0.87			0.114			2.36			0.128			0.83			0.151			3.13			0.128			2.65		
VKA> 5.5		240		5.451			0.062			1.14			0.164			3.01			0.175			0.00			0.170			3.12			0.175			3.22		
^CCN+		240		1.091			0.010			0.92			0.014			1.28			0.017			0.00			0.016			1.47			0.017			1.58		

[Table 3 on page 5]
	All Lots (seconds)					Repeatability						Between-run						Between-day						Between-lot						Within-lab				
	Sample	N			Mean	SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV	
Normal 1		240		14.401		0.191		1.33			0.159			1.10			0.260			0.52			0.000			0.00			0.260			1.80		
Normal 2		240		14.132		0.209		1.48			0.246			1.74			0.353			1.00			0.000			0.00			0.353			2.50		
VKA
2≤INR≤3		240		29.531		0.589		1.99			1.053			3.57			1.207			0.00			0.136			0.46			1.207			4.09		
VKA		240		44.070		0.870		1.97			1.635			3.71			1.852			0.00			0.478			1.08			1.852			4.20		

--- Page 6 ---
All Lots (seconds) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
3<INR≤4
VKA
240 61.342 0.974 1.59 2.791 4.55 2.956 0.00 0.474 0.77
4.5<INR≤5.5 2.956 4.82
VKA>5.5 240 69.433 1.444 2.08 3.209 4.62 3.519 0.00 0.289 0.42 3.519 5.07
Def V 240 25.510 0.420 1.65 0.924 3.62 1.015 0.00 0.177 0.69 1.015 3.98
*SCN 240 14.865 0.236 1.59 0.203 1.37 0.324 0.61 0.000 0.00 0.324 2.18
*SCP 240 25.030 0.402 1.61 0.890 3.56 0.977 0.00 0.196 0.78 0.977 3.90
^CCN+ 240 14.929 0.263 1.76 0.139 0.93 0.332 0.99 0.000 0.00 0.332 2.23
^CCABN+ 240 37.850 0.625 1.65 1.188 3.14 1.342 0.00 0.408 1.08 1.342 3.55
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Repeatability on STA Compact Max, INR
All Lots (INR) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 240 1.053 0.014 1.33 0.012 1.14 0.006 0.57 0.018 1.71 0.019 1.84
Normal 2 240 1.032 0.016 1.55 0.019 1.84 0.010 0.97 0.016 1.55 0.027 2.59
VKA
240 2.213 0.046 2.08 0.082 3.71 0.000 0.00 0.067 3.03 0.094 4.25
2≤INR≤3
VKA
240 3.348 0.067 2.00 0.129 3.85 0.000 0.00 0.144 4.30 0.145 4.34
3<INR≤4
VKA
240 4.711 0.078 1.66 0.222 4.71 0.000 0.00 0.204 4.33 0.235 4.99
4.5<INR≤5.5
VKA>5.5 240 5.355 0.115 2.15 0.257 4.80 0.000 0.00 0.237 4.43 0.282 5.26
^CCN+ 240 1.093 0.020 1.83 0.011 1.01 0.011 1.01 0.019 1.74 0.025 2.32
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Repeatability on STA Satellite, PT in seconds
All Lots (seconds) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 240 14.108 0.139 0.99 0.218 1.55 0.000 0.00 0.112 0.79 0.259 1.83
Normal 2 240 13.639 0.165 1.21 0.202 1.48 0.000 0.00 0.136 1.00 0.261 1.91
VKA
240 29.791 0.439 1.47 0.731 2.45 0.000 0.00 0.000 0.00 0.853 2.86
2≤INR≤3
VKA
240 44.366 0.695 1.57 0.983 2.22 0.313 0.71 0.563 1.27 1.244 2.80
3<INR≤4
VKA
240 64.173 0.688 1.07 2.063 3.21 0.227 0.35 0.666 1.04 2.187 3.41
INR> 4.5
VKA
240 71.376 1.334 1.87 2.307 3.23 0.000 0.00 0.590 0.83 2.665 3.73
INR>4.5
Def V 240 24.988 0.267 1.07 0.505 2.02 0.000 0.00 0.000 0.00 0.571 2.29
*SCN 240 14.557 0.221 1.52 0.242 1.66 0.081 0.56 0.025 0.17 0.338 2.32
*SCP 240 25.170 0.345 1.37 0.709 2.82 0.000 0.00 0.000 0.00 0.788 3.13
^CCN+ 240 14.665 0.140 0.95 0.172 1.17 0.070 0.48 0.074 0.50 0.233 1.59
^CCABN+ 240 38.025 0.559 1.47 1.211 3.18 0.000 0.00 0.266 0.70 1.334 3.51
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
K211485 - Page 6 of 13

[Table 1 on page 6]
	All Lots (seconds)				Repeatability		Between-run		Between-day		Between-lot			Within-lab		
	Sample		N	Mean	SD	%CV	SD	%CV	SD	%CV	SD	%CV		SD	%CV	
3<INR≤4																
VKA
4.5<INR≤5.5		240		61.342	0.974	1.59	2.791	4.55	2.956	0.00	0.474	0.77	2.956		4.82	
VKA>5.5		240		69.433	1.444	2.08	3.209	4.62	3.519	0.00	0.289	0.42	3.519		5.07	
Def V		240		25.510	0.420	1.65	0.924	3.62	1.015	0.00	0.177	0.69	1.015		3.98	
*SCN		240		14.865	0.236	1.59	0.203	1.37	0.324	0.61	0.000	0.00	0.324		2.18	
*SCP		240		25.030	0.402	1.61	0.890	3.56	0.977	0.00	0.196	0.78	0.977		3.90	
^CCN+		240		14.929	0.263	1.76	0.139	0.93	0.332	0.99	0.000	0.00	0.332		2.23	
^CCABN+		240		37.850	0.625	1.65	1.188	3.14	1.342	0.00	0.408	1.08	1.342		3.55	

[Table 2 on page 6]
	All Lots (INR)				Repeatability		Between-run		Between-day		Between-lot			Within-lab			
	Sample		N	Mean	SD	%CV	SD	%CV	SD	%CV	SD	%CV		SD		%CV	
Normal 1		240		1.053	0.014	1.33	0.012	1.14	0.006	0.57	0.018	1.71	0.019		1.84		
Normal 2		240		1.032	0.016	1.55	0.019	1.84	0.010	0.97	0.016	1.55	0.027		2.59		
VKA
2≤INR≤3		240		2.213	0.046	2.08	0.082	3.71	0.000	0.00	0.067	3.03	0.094		4.25		
VKA
3<INR≤4		240		3.348	0.067	2.00	0.129	3.85	0.000	0.00	0.144	4.30	0.145		4.34		
VKA
4.5<INR≤5.5		240		4.711	0.078	1.66	0.222	4.71	0.000	0.00	0.204	4.33	0.235		4.99		
VKA>5.5		240		5.355	0.115	2.15	0.257	4.80	0.000	0.00	0.237	4.43	0.282		5.26		
^CCN+		240		1.093	0.020	1.83	0.011	1.01	0.011	1.01	0.019	1.74	0.025		2.32		

[Table 3 on page 6]
	All Lots (seconds)							R	epeatability					B	etween-run					B	etween-day						Between-lot					Within-lab			
	Sample		N		M	ean			SD		%	CV			SD		%	CV			SD		%	CV			SD			%CV		SD		%CV	
Normal 1			240		14.108			0.139			0.99			0.218			1.55			0.000			0.00			0.112			0.79			0.259		1.83	
Normal 2			240		13.639			0.165			1.21			0.202			1.48			0.000			0.00			0.136			1.00			0.261		1.91	
VKA
2≤INR≤3			240		29.791			0.439			1.47			0.731			2.45			0.000			0.00			0.000			0.00			0.853		2.86	
VKA
3<INR≤4			240		44.366			0.695			1.57			0.983			2.22			0.313			0.71			0.563			1.27			1.244		2.80	
VKA
INR> 4.5			240		64.173			0.688			1.07			2.063			3.21			0.227			0.35			0.666			1.04			2.187		3.41	
VKA
INR>4.5			240		71.376			1.334			1.87			2.307			3.23			0.000			0.00			0.590			0.83			2.665		3.73	
Def V			240		24.988			0.267			1.07			0.505			2.02			0.000			0.00			0.000			0.00			0.571		2.29	
*SCN			240		14.557			0.221			1.52			0.242			1.66			0.081			0.56			0.025			0.17			0.338		2.32	
*SCP			240		25.170			0.345			1.37			0.709			2.82			0.000			0.00			0.000			0.00			0.788		3.13	
^CCN+			240		14.665			0.140			0.95			0.172			1.17			0.070			0.48			0.074			0.50			0.233		1.59	
^CCABN+			240		38.025			0.559			1.47			1.211			3.18			0.000			0.00			0.266			0.70			1.334		3.51	

--- Page 7 ---
Repeatability on STA Satellite, INR
All Lots (INR) Repeatability Between-run Between-day Between-lot Within-lab
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 240 1.038 0.011 1.06 0.016 1.54 0.000 0.00 0.009 0.87 0.019 1.87
Normal 2 240 1.003 0.013 1.30 0.016 1.59 0.000 0.00 0.009 0.90 0.021 2.05
VKA 240 2.255 0.034 1.51 0.057 2.53 0.000 0.00 0.042 1.86 0.066 2.94
2≤INR≤3
VKA 240 3.408 0.055 1.61 0.080 2.35 0.026 0.76 0.103 3.02 0.101 2.95
3<INR≤4
VKA 240 4.997 0.055 1.10 0.166 3.32 0.014 0.28 0.163 3.26 0.175 3.51
INR>4.5
VKA 240 5.580 0.108 1.94 0.190 3.41 0.000 0.00 0.181 3.24 0.219 3.92
INR>4.5
^CCN+ 240 1.081 0.012 1.11 0.013 1.20 0.006 0.55 0.013 1.20 0.019 1.73
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
A multi-site reproducibility study was performed at three clinical sites. The study was assessed
using three lots of STA - NeoPTimal on a representative of each analyzer family: STA-R, STA
Compact and STA Satellite. The study conducted for five days with two runs per day and three
replicates per run by a minimum of two operators. The STA - NeoPTimal demonstrated
acceptable reproducibility when evaluated using control material and 3.2% citrated patient
plasma samples. The reproducibility study results for a representative of each analyzer family for
PT in seconds and INR are summarized in tables below.
Summary of Multi-Site Reproducibility Results on STA-R Max in PT seconds
All Data (seconds) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 270 14.662 0.139 0.95 0.153 1.04 0.000 0.00 0.016 0.11 0.396 2.70 0.447 3.05
Normal 2 270 14.272 0.137 0.96 0.142 0.99 0.000 0.00 0.005 0.04 0.420 2.94 0.464 3.25
VKA
270 31.279 0.298 0.95 0.584 1.87 0.000 0.00 0.242 0.77 0.837 2.68 1.090 3.48
2≤INR≤3
VKA
270 46.034 0.358 0.78 0.905 1.97 0.000 0.00 0.359 0.78 0.999 2.17 1.440 3.13
3<INR≤4
VKA
270 63.011 0.505 0.80 1.251 1.99 0.000 0.00 0.753 1.20 1.288 2.04 2.011 3.19
4.5<INR≤5.5
VKA >5.5 270 71.215 0.727 1.02 1.393 1.96 0.000 0.00 0.796 1.12 1.895 2.66 2.587 3.63
Def V 270 26.671 0.241 0.90 0.508 1.90 0.000 0.00 0.244 0.91 0.605 2.27 0.861 3.23
*SCN 270 15.267 0.159 1.04 0.192 1.26 0.000 0.00 0.000 0.00 0.358 2.34 0.436 2.86
*SCP 270 26.298 0.235 0.89 0.503 1.91 0.000 0.00 0.181 0.69 0.435 1.65 0.728 2.77
^CCN+ 270 15.269 0.174 1.14 0.138 0.90 0.000 0.00 0.040 0.26 0.384 2.51 0.446 2.92
^CCABN+ 270 39.033 0.335 0.86 1.007 2.58 0.000 0.00 0.219 0.56 0.672 1.72 1.275 3.27
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Summary of Multi-Site Reproducibility Results on STA-R Max, INR
All Data (INR) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 270 1.072 0.010 0.93 0.012 1.12 0.000 0.00 0.016 1.49 0.029 2.70 0.036 3.36
Normal 2 270 1.043 0.010 0.96 0.012 1.15 0.000 0.00 0.016 1.53 0.030 2.88 0.037 3.55
VKA
270 2.347 0.023 0.98 0.046 1.96 0.000 0.00 0.048 2.04 0.059 2.51 0.092 3.92
2≤INR≤3
K211485 - Page 7 of 13

[Table 1 on page 7]
All Lots (INR)			Repeatability		Between-run		Between-day		Between-lot		Within-lab	
Sample	N	Mean	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
Normal 1	240	1.038	0.011	1.06	0.016	1.54	0.000	0.00	0.009	0.87	0.019	1.87
Normal 2	240	1.003	0.013	1.30	0.016	1.59	0.000	0.00	0.009	0.90	0.021	2.05
VKA
2≤INR≤3	240	2.255	0.034	1.51	0.057	2.53	0.000	0.00	0.042	1.86	0.066	2.94
VKA
3<INR≤4	240	3.408	0.055	1.61	0.080	2.35	0.026	0.76	0.103	3.02	0.101	2.95
VKA
INR>4.5	240	4.997	0.055	1.10	0.166	3.32	0.014	0.28	0.163	3.26	0.175	3.51
VKA
INR>4.5	240	5.580	0.108	1.94	0.190	3.41	0.000	0.00	0.181	3.24	0.219	3.92
^CCN+	240	1.081	0.012	1.11	0.013	1.20	0.006	0.55	0.013	1.20	0.019	1.73

[Table 2 on page 7]
All Data (seconds)			Repeatability		Between-run		Between-day		Between-lot		Between-site		Reproducibility	
Sample	N	Mean	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
Normal 1	270	14.662	0.139	0.95	0.153	1.04	0.000	0.00	0.016	0.11	0.396	2.70	0.447	3.05
Normal 2	270	14.272	0.137	0.96	0.142	0.99	0.000	0.00	0.005	0.04	0.420	2.94	0.464	3.25
VKA
2≤INR≤3	270	31.279	0.298	0.95	0.584	1.87	0.000	0.00	0.242	0.77	0.837	2.68	1.090	3.48
VKA
3<INR≤4	270	46.034	0.358	0.78	0.905	1.97	0.000	0.00	0.359	0.78	0.999	2.17	1.440	3.13
VKA
4.5<INR≤5.5	270	63.011	0.505	0.80	1.251	1.99	0.000	0.00	0.753	1.20	1.288	2.04	2.011	3.19
VKA >5.5	270	71.215	0.727	1.02	1.393	1.96	0.000	0.00	0.796	1.12	1.895	2.66	2.587	3.63
Def V	270	26.671	0.241	0.90	0.508	1.90	0.000	0.00	0.244	0.91	0.605	2.27	0.861	3.23
*SCN	270	15.267	0.159	1.04	0.192	1.26	0.000	0.00	0.000	0.00	0.358	2.34	0.436	2.86
*SCP	270	26.298	0.235	0.89	0.503	1.91	0.000	0.00	0.181	0.69	0.435	1.65	0.728	2.77
^CCN+	270	15.269	0.174	1.14	0.138	0.90	0.000	0.00	0.040	0.26	0.384	2.51	0.446	2.92
^CCABN+	270	39.033	0.335	0.86	1.007	2.58	0.000	0.00	0.219	0.56	0.672	1.72	1.275	3.27

[Table 3 on page 7]
All Data (INR)									Repeatability						Between-run				Between-day						Between-lot				Between-site					Reproducibility			
Sample			N			Mean			SD			%CV			SD		%CV		SD		%	CV			SD	%	CV		SD			%CV		SD			%CV
Normal 1		270			1.072			0.010			0.93			0.012		1.12		0.000			0.00			0.016		1.49		0.029			2.70		0.036				
Normal 2		270			1.043			0.010			0.96			0.012		1.15		0.000			0.00			0.016		1.53		0.030			2.88		0.037				
VKA
2≤INR≤3		270			2.347			0.023			0.98			0.046		1.96		0.000			0.00			0.048		2.04		0.059			2.51		0.092				

--- Page 8 ---
All Data (INR) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
VKA
270 3.500 0.028 0.80 0.072 2.06 0.000 0.00 0.086 2.46 0.063 1.80 0.132 3.77
3<INR≤4
VKA
270 4.840 0.041 0.85 0.100 2.07 0.000 0.00 0.116 2.40 0.084 1.74 0.180 3.72
INR>4.5
VKA
270 5.494 0.057 1.04 0.112 2.04 0.000 0.00 0.149 2.71 0.129 2.35 0.234 4.26
INR>4.5
^CCN+ 270 1.119 0.013 1.16 0.011 0.98 0.000 0.00 0.015 1.34 0.028 2.50 0.036 3.22
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Summary of Multi-Site Reproducibility Results on STA Compact Max in PT seconds
All Data (seconds) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 270 14.622 0.182 1.24 0.186 1.27 0.094 0.64 0.126 0.86 0.276 1.89 0.411 2.81
Normal 2 270 14.291 0.182 1.27 0.242 1.69 0.000 0.00 0.138 0.97 0.171 1.20 0.374 2.62
VKA
270 30.786 0.604 1.96 0.645 2.10 0.107 0.35 0.294 0.95 1.283 4.17 1.589 5.16
2≤INR≤3
VKA
270 45.475 0.627 1.38 1.098 2.41 0.414 0.91 0.292 0.64 1.241 2.73 1.843 4.05
3<INR≤4
VKA
270 62.711 0.917 1.46 1.773 2.83 0.582 0.93 0.000 0.00 1.665 2.66 2.664 4.25
4.5<INR≤5.5
VKA >5.5 270 70.780 1.379 1.95 2.379 3.36 0.000 0.00 0.621 0.88 2.317 3.27 3.649 5.16
Def V 270 26.370 0.411 1.56 0.563 2.14 0.000 0.00 0.500 1.90 0.850 3.22 1.207 4.58
*SCN 270 15.233 0.182 1.19 0.237 1.56 0.000 0.00 0.113 0.74 0.323 2.12 0.454 2.98
*SCP 270 26.111 0.436 1.67 0.558 2.14 0.000 0.00 0.229 0.88 0.902 3.45 1.170 4.48
^CCN+ 270 15.190 0.174 1.15 0.266 1.75 0.000 0.00 0.103 0.68 0.248 1.63 0.416 2.74
^CCABN+ 270 39.131 0.544 1.39 0.926 2.37 0.000 0.00 0.381 0.97 1.199 3.06 1.654 4.23
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Summary of Multi-Site Reproducibility Results on STA Compact Max, INR
All Data (INR) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 270 1.070 0.014 1.31 0.014 1.31 0.008 0.75 0.026 2.43 0.016 1.50 0.038 3.55
Normal 2 270 1.044 0.014 1.34 0.018 1.72 0.000 0.00 0.027 2.59 0.000 0.00 0.035 3.35
VKA
270 2.310 0.046 1.99 0.050 2.16 0.007 0.30 0.085 3.68 0.088 3.81 0.140 6.06
2≤INR≤3
VKA
270 3.457 0.050 1.45 0.087 2.52 0.030 0.87 0.139 4.02 0.057 1.65 0.183 5.29
3<INR≤4
VKA
270 4.819 0.073 1.51 0.143 2.97 0.043 0.89 0.189 3.92 0.074 1.54 0.262 5.44
4.5<INR≤5.5
VKA >5.5 270 5.462 0.111 2.03 0.193 3.53 0.000 0.00 0.236 4.32 0.131 2.40 0.350 6.41
^CCN+ 270 1.113 0.014 1.26 0.021 1.89 0.000 0.00 0.026 2.34 0.013 1.17 0.038 3.42
Summary of Multi-Site Reproducibility Results on STA Satellite in PT seconds
All Data (seconds) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 270 14.370 0.166 1.16 0.203 1.41 0.000 0.00 0.196 1.36 0.225 1.57 0.397 2.76
Normal 2 270 13.957 0.130 0.93 0.216 1.55 0.000 0.00 0.200 1.43 0.223 1.60 0.392 2.81
K211485 - Page 8 of 13

[Table 1 on page 8]
All Data (INR)									Repeatability						Between-run						Between-day						Between-lot				Between-site						Reproducibility				
Sample			N			Mean			SD			%CV			SD			%CV			SD			%CV			SD		%CV		SD			%CV			SD			%CV	
VKA
3<INR≤4		270			3.500			0.028			0.80			0.072			2.06			0.000			0.00			0.086			2.46 0		.063		1.80			0.132			3.77		
VKA
INR>4.5		270			4.840			0.041			0.85			0.100			2.07			0.000			0.00			0.116			2.40 0		.084		1.74			0.180			3.72		
VKA
INR>4.5		270			5.494			0.057			1.04			0.112			2.04			0.000			0.00			0.149			2.71 0		.129		2.35			0.234			4.26		
^CCN+		270			1.119			0.013			1.16			0.011			0.98			0.000			0.00			0.015			1.34 0		.028		2.50			0.036			3.22		

[Table 2 on page 8]
All Data (seconds)			Repeatability		Between-run		Between-day		Between-lot		Between-site		Reproducibility	
Sample	N	Mean	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV	SD	%CV
Normal 1	270	14.622	0.182	1.24	0.186	1.27	0.094	0.64	0.126	0.86	0.276	1.89	0.411	2.81
Normal 2	270	14.291	0.182	1.27	0.242	1.69	0.000	0.00	0.138	0.97	0.171	1.20	0.374	2.62
VKA
2≤INR≤3	270	30.786	0.604	1.96	0.645	2.10	0.107	0.35	0.294	0.95	1.283	4.17	1.589	5.16
VKA
3<INR≤4	270	45.475	0.627	1.38	1.098	2.41	0.414	0.91	0.292	0.64	1.241	2.73	1.843	4.05
VKA
4.5<INR≤5.5	270	62.711	0.917	1.46	1.773	2.83	0.582	0.93	0.000	0.00	1.665	2.66	2.664	4.25
VKA >5.5	270	70.780	1.379	1.95	2.379	3.36	0.000	0.00	0.621	0.88	2.317	3.27	3.649	5.16
Def V	270	26.370	0.411	1.56	0.563	2.14	0.000	0.00	0.500	1.90	0.850	3.22	1.207	4.58
*SCN	270	15.233	0.182	1.19	0.237	1.56	0.000	0.00	0.113	0.74	0.323	2.12	0.454	2.98
*SCP	270	26.111	0.436	1.67	0.558	2.14	0.000	0.00	0.229	0.88	0.902	3.45	1.170	4.48
^CCN+	270	15.190	0.174	1.15	0.266	1.75	0.000	0.00	0.103	0.68	0.248	1.63	0.416	2.74
^CCABN+	270	39.131	0.544	1.39	0.926	2.37	0.000	0.00	0.381	0.97	1.199	3.06	1.654	4.23

[Table 3 on page 8]
All Data (INR)						Repeatability				Between-run				Between-day				Between-lot				Between-site				Reproducibility			
Sample		N		Mean		SD		%CV		SD		%CV		SD		%CV		SD		%CV		SD		%CV		SD		%CV	
Normal 1	270		1.070		0.014		1.31		0.014		1.31		0.008		0.75		0.026		2.43		0.016		1.50		0.038		3.55		
Normal 2	270		1.044		0.014		1.34		0.018		1.72		0.000		0.00		0.027		2.59		0.000		0.00		0.035		3.35		
VKA
2≤INR≤3	270		2.310		0.046		1.99		0.050		2.16		0.007		0.30		0.085		3.68		0.088		3.81		0.140		6.06		
VKA
3<INR≤4	270		3.457		0.050		1.45		0.087		2.52		0.030		0.87		0.139		4.02		0.057		1.65		0.183		5.29		
VKA
4.5<INR≤5.5	270		4.819		0.073		1.51		0.143		2.97		0.043		0.89		0.189		3.92		0.074		1.54		0.262		5.44		
VKA >5.5	270		5.462		0.111		2.03		0.193		3.53		0.000		0.00		0.236		4.32		0.131		2.40		0.350		6.41		
^CCN+	270		1.113		0.014		1.26		0.021		1.89		0.000		0.00		0.026		2.34		0.013		1.17		0.038		3.42		

[Table 4 on page 8]
All Data (seconds)						Repeatability				Between-run				Between-day				Between-lot		Between-site				Reproducibility			
Sample		N		Mean		SD		%CV		SD		%CV		SD		%CV		SD	%CV	SD		%CV		SD		%CV	
Normal 1		270		14.370		0.166		1.16		0.203		1.41		0.000		0.00		0.196	1.36	0.225		1.57		0.397		2.76	
Normal 2		270		13.957		0.130		0.93		0.216		1.55		0.000		0.00		0.200	1.43	0.223		1.60		0.392		2.81	

--- Page 9 ---
All Data (seconds) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
VKA
270 31.016 0.510 1.64 1.039 3.35 0.000 0.00 0.534 1.72 1.251 4.03 1.786 5.76
2≤INR≤3
VKA
270 46.346 0.600 1.29 1.110 2.40 0.000 0.00 0.744 1.61 1.484 3.20 2.085 4.50
3<INR≤4
VKA
270 66.456 0.829 1.25 1.457 2.19 0.212 0.32 0.836 1.26 1.893 2.85 2.672 4.02
INR>4.5
VKA
270 74.733 1.331 1.78 2.262 3.03 0.000 0.00 1.455 1.95 3.260 4.36 4.432 5.93
INR>4.5
Def V 270 25.763 0.387 1.50 0.532 2.06 0.000 0.00 0.180 0.70 0.776 3.01 1.033 4.01
*SCN 270 14.878 0.220 1.48 0.241 1.62 0.000 0.00 0.229 1.54 0.385 2.59 0.554 3.72
*SCP 270 25.845 0.372 1.44 0.573 2.22 0.000 0.00 0.375 1.45 0.741 2.87 1.075 4.16
^CCN+ 270 14.926 0.154 1.03 0.229 1.53 0.000 0.00 0.180 1.21 0.309 2.07 0.452 3.03
^CCABN+ 270 39.160 0.618 1.58 1.013 2.59 0.000 0.00 0.848 2.17 1.130 2.89 1.845 4.71
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
Summary of Multi-Site Reproducibility Results on STA Satellite, INR
All Data (seconds) Repeatability Between-run Between-day Between-lot Between-site Reproducibility
Sample N Mean SD %CV SD %CV SD %CV SD %CV SD %CV SD %CV
Normal 1 270 1.059 0.012 1.13 0.016 1.51 0.000 0.00 0.020 1.89 0.015 1.42 0.032 3.02
Normal 2 270 1.028 0.010 0.97 0.016 1.56 0.000 0.00 0.020 1.95 0.015 1.46 0.032 3.11
VKA
270 2.352 0.039 1.66 0.082 3.49 0.000 0.00 0.088 3.74 0.088 3.74 0.154 6.55
2≤INR≤3
VKA
270 3.567 0.048 1.35 0.088 2.47 0.000 0.00 0.145 4.06 0.091 2.55 0.198 5.55
3<INR≤4
VKA
270 5.183 0.068 1.31 0.117 2.26 0.014 0.27 0.204 3.94 0.105 2.03 0.267 5.15
INR>4.5
VKA
270 5.855 0.108 1.84 0.183 3.13 0.000 0.00 0.293 5.00 0.215 3.67 0.421 7.19
INR>4.5
^CCN+ 270 1.101 0.012 1.09 0.018 1.63 0.000 0.00 0.023 2.09 0.021 1.91 0.038 3.45
*SCN: STA – System Control N, SCP: STA– System Control P, Normal and Abnormal Control Materials
^CCN+ : STA – Coag Control N Plus, CCABN+ : Coag Control ABN Plus, Normal and Abnormal Control Materials
2. Linearity:
Not applicable
3. Analytical Specificity/Interference:
In the interference studies, a total of four samples (patient sample within normal reference
range, VKA patient samples with 2 ≤ INR ≤ 3, VKA patient samples with 3.1 ≤ INR ≤ 4.5
and Deficient V patient sample) were evaluated in triplicate with three lots of STA -
NeoPTimal reagent, on the STA-R family, STA Compact family and STA Satellite
instrumentation on pair of plasma samples consisting of a control and a test sample. The
common exogenous and endogenous interfering substances and their interference results are
listed below and showed no significant interference up to the indicated concentration for all
samples tested.
K211485 - Page 9 of 13

[Table 1 on page 9]
	All Data (seconds)									Repeatability						Between-run						Between-day						Between-lot						Between-site						Reproducibility				
	Sample			N			Mean			SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV	
VKA
2≤INR≤3			270			31.016			0.510			1.64			1.039			3.35			0.000			0.00			0.534			1.72			1.251			4.03			1.786			5.76		
VKA
3<INR≤4			270			46.346			0.600			1.29			1.110			2.40			0.000			0.00			0.744			1.61			1.484			3.20			2.085			4.50		
VKA
INR>4.5			270			66.456			0.829			1.25			1.457			2.19			0.212			0.32			0.836			1.26			1.893			2.85			2.672			4.02		
VKA
INR>4.5			270			74.733			1.331			1.78			2.262			3.03			0.000			0.00			1.455			1.95			3.260			4.36			4.432			5.93		
Def V			270			25.763			0.387			1.50			0.532			2.06			0.000			0.00			0.180			0.70			0.776			3.01			1.033			4.01		
*SCN			270			14.878			0.220			1.48			0.241			1.62			0.000			0.00			0.229			1.54			0.385			2.59			0.554			3.72		
*SCP			270			25.845			0.372			1.44			0.573			2.22			0.000			0.00			0.375			1.45			0.741			2.87			1.075			4.16		
^CCN+			270			14.926			0.154			1.03			0.229			1.53			0.000			0.00			0.180			1.21			0.309			2.07			0.452			3.03		
^CCABN+			270			39.160			0.618			1.58			1.013			2.59			0.000			0.00			0.848			2.17			1.130			2.89			1.845			4.71		

[Table 2 on page 9]
	All Data (seconds)									Repeatability						Between-run						Between-day						Between-lot						Between-site						Reproducibility				
	Sample			N			Mean			SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV			SD			%CV	
Normal 1			270			1.059			0.012			1.13			0.016			1.51			0.000			0.00			0.020			1.89			0.015			1.42			0.032			3.02		
Normal 2			270			1.028			0.010			0.97			0.016			1.56			0.000			0.00			0.020			1.95			0.015			1.46			0.032			3.11		
VKA
2≤INR≤3			270			2.352			0.039			1.66			0.082			3.49			0.000			0.00			0.088			3.74			0.088			3.74			0.154			6.55		
VKA
3<INR≤4			270			3.567			0.048			1.35			0.088			2.47			0.000			0.00			0.145			4.06			0.091			2.55			0.198			5.55		
VKA
INR>4.5			270			5.183			0.068			1.31			0.117			2.26			0.014			0.27			0.204			3.94			0.105			2.03			0.267			5.15		
VKA
INR>4.5			270			5.855			0.108			1.84			0.183			3.13			0.000			0.00			0.293			5.00			0.215			3.67			0.421			7.19		
^CCN+			270			1.101			0.012			1.09			0.018			1.63			0.000			0.00			0.023			2.09			0.021			1.91			0.038			3.45		

--- Page 10 ---
Interferent Highest Concentration with No Interference
Hemoglobin 4000 mg/dL
Conjugated Bilirubin 29 mg/dL
Unconjugated Bilirubin 20 mg/dL
Triglycerides 3270 mg/dL
Unfractionated Heparin (UFH) 1.0 IU/mL
Low Molecular Weight Heparin (LMWH) 1.5 IU anti Xa/mL
Apixaban 13 ng/mL
Dabigatran 3 ng/mL
Rivaroxaban 7 ng/mL
Edoxaban 6 ng/mL
Daptomycin
According to the drug manufacturer, Daptomycin may artificially prolong PT and INR in
patients with normal renal function for up to nine hours and for patients with renal
impairment up to 28 hours. Therefore, PT or INR monitoring of patients on Daptomycin may
be affected for up to 28 hours after dosing.
Extrinsic Factor Sensitivity
Factor sensitivity study was designed in accordance with the CLSI H47-A2 and the CLSI
H48, 2nd Edition. The study was performed for factors II, V, VII and X using three lots of
STA - NeoPTimal on STA-R family analyzers. For each of the extrinsic factors, a
commercial single factor-deficient plasma was mixed with normal pool plasma up to eight
dilutions. PT was determined in seconds in duplicate for each specific factor dilution. The
sensitivity estimate determined is shown in the table below:
Extrinsic Factor Mean (%)
Factor II 46%
Factor V 59%
Factor VII 55%
Factor X 65%
4. Assay Reportable Range:
Not applicable
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
Quality Control
The STA- System control N + P (K943518) and STA - Coag Control (N+ABN) PLUS
(K120014) are used to perform quality control for the PT assay.
Sample Stability Study
a. At room temperature: To demonstrate that the citrated plasma samples remain stable for
24 hours (h) when stored at room temperature, four normal patient samples and eight
VKA samples with INR between 1.5–5.5 were tested in triplicate with one lot of STA -
NeoPTimal on the STA-R family of analyzers. Samples were tested at time points: 0 h, 6
K211485 - Page 10 of 13

[Table 1 on page 10]
Interferent	Highest Concentration with No Interference
Hemoglobin	4000 mg/dL
Conjugated Bilirubin	29 mg/dL
Unconjugated Bilirubin	20 mg/dL
Triglycerides	3270 mg/dL
Unfractionated Heparin (UFH)	1.0 IU/mL
Low Molecular Weight Heparin (LMWH)	1.5 IU anti Xa/mL
Apixaban	13 ng/mL
Dabigatran	3 ng/mL
Rivaroxaban	7 ng/mL
Edoxaban	6 ng/mL

[Table 2 on page 10]
	Extrinsic Factor			Mean (%)	
Factor II			46%		
Factor V			59%		
Factor VII			55%		
Factor X			65%		

--- Page 11 ---
h, 8 h, 21 h, 24 h and 25 h. The results support a plasma stability claim of 24 h at room
temperature (18–25 °C).
b. Long-term frozen plasma stability: The long-term frozen sample stability study was done
to establish the stability of samples for testing with STA - NeoPTimal and assess the
stability of samples under intended storage conditions as recommended in CLSI H21-A5.
A total of 53 citrated plasma samples (19 normal patient samples and 24 VKA samples
with INR between 1.5–5.0) were tested in triplicate with STA - NeoPTimal on one STA-
R family analyzer. Samples were tested fresh (T=0) and then frozen at -80°C. The frozen
sample stability at -80°C was tested at different time points (2, 7, 8, 12 and 20 months).
Data support a frozen plasma stability claim of 12 months at -80°C.
Reagent Stability Study
a. Shelf-life Stability: Study was conducted according to CLSI EP25-A. Six lots of STA -
NeoPTimal were used for the shelf-life study (three lots for the 5 mL kit and three lots for
the 10 mL kit). Both quality control and 3.2% citrated plasma samples were tested at
different time points in triplicate on STA-R Evolution. Six timepoints were tested (0, 6,
12, 18, 24 and 25 months). Each sample was tested at each time point with three different
vials of each lot of STA - NeoPTimal in triplicate. The results support a 24-month shelf-
life claim at 2–8°C.
b. In-Use Stability: To assess the in-use stability of the STA - NeoPTimal, the study was
performed with three lots of STA - NeoPTimal representing the two different volume
configurations (5 mL and 10 mL) on the STA-R family, STA Compact family and STA
Satellite instrumentation. To assess the stability of STA - NeoPTimal at 2–8°C, three lots
of reagents were tested on STA-R analyzer. Testing was performed on six samples:
• Patient sample included in the normal reference range (Normal)
• VKA patient sample with an INR between 2.0 and 3.0 (VKA 2–3)
• VKA patient sample with an INR between 3.1 and 4.5 (VKA 3–4.5)
• Deficient patient sample (Def V)
• Two controls
All samples were tested after reconstitution in triplicate at different timepoints. The study
results support the following in-use stability claim:
STA - NeoPTimal STA - NeoPTimal
5 mL 10 mL
STA-R Family,
48 h on board
STA Compact Family
4 days on board
STA Satellite Family
8 days
2–8°C
c. Transportation Stability Studies: The shipping study was conducted to evaluate the
performance of STA - NeoPTimal throughout its claimed shelf-life when exposed to
conditions experienced during transport. Two lots of STA - NeoPTimal (one for 5 mL
and one for 10 mL) were subjected to simulated shipping conditions and thermal shipping
stress. Each lot was stored according to specified transport conditions. After the cycle for
transport condition simulation, reagents were stored unopened at 2–8°C. At different time
points (0, 6, 12, 18, 24 and 25 months), the reagents were reconstituted and PT was
K211485 - Page 11 of 13

[Table 1 on page 11]
	STA - NeoPTimal	STA - NeoPTimal
	5 mL	10 mL
STA-R Family,
STA Compact Family	48 h on board	
STA Satellite Family	4 days on board	
2–8°C	8 days	

--- Page 12 ---
performed (results expressed as seconds, and INR for normal and VKA samples) on
different samples in triplicate. The results demonstrate transport stability of STA -
NeoPTimal under stress conditions.
6. Detection Limit:
Not applicable
7. Assay Cut-Off:
Not applicable
B Comparison Studies:
1. Method Comparison with Predicate Device:
The method comparison study was performed for both Prothrombin Time (PT) in seconds
and INR at three sites. Samples were collected in 3.2% sodium citrate and assayed in parallel
and in random order on both the candidate and predicate device. At each site, one analyzer
per family was used for analysis with three lots of reagents. A total of 683 patient samples
were included in data analysis. The results were evaluated using a Passing-Bablok regression
analysis for each site and all sites combined. The results are summarized in the following
tables:
Passing-Bablok regression analyses for all sites combined
N Range Slope (95% CI) Intercept (95% CI) Pearson (r)
1.07 0.16
683 10.3–95.9 0.967
PT (Seconds) (1.05, 1.09) (-0.14, 0.46)
0.93 0.04
INR 683 0.78–7.62 0.965
(0.92, 0.95) (0.02, 0.06)
2. Matrix Comparison:
The sample matrix comparison studies were performed to determine the effect of freezing
plasma samples on the PT test. The comparability of results for samples tested fresh and after
one week of storage at -80ºC (fresh vs frozen) was assessed. Each sample was tested using
one lot of STA - NeoPTimal on one analyzer of the STA-R family. A total of 40 patient
samples were tested in duplicate. Specifically, 15 patient samples in the normal reference
range and 25 VKA patient samples. Results in both INR and PT (seconds) met the
acceptance criteria, demonstrating the STA - NeoPTimal reports comparable results on fresh
and frozen plasma samples.
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable
2. Clinical Specificity:
K211485 - Page 12 of 13

[Table 1 on page 12]
	N	Range	Slope (95% CI)	Intercept (95% CI)	Pearson (r)
PT (Seconds)	683	10.3–95.9	1.07
(1.05, 1.09)	0.16
(-0.14, 0.46)	0.967
INR	683	0.78–7.62	0.93
(0.92, 0.95)	0.04
(0.02, 0.06)	0.965

--- Page 13 ---
Not applicable
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable
D Clinical Cut-Off:
Not applicable
E Expected Values/Reference Range:
The study was conducted to determine the reference range of STA - NeoPTimal for PT in
seconds and INR. The reference interval study was performed at three sites with a total of 137
reference samples obtained from apparently healthy individuals > 21 years of age. The reference
range of STA - NeoPTimal was calculated in accordance with the CLSI EP28-A3c, as shown in
the following table.
2.5% percentiles 97.5% percentiles
Test (units)
(95% CI) (95% CI)
11.8 14.9
PT (seconds)
(11.6, 11.9) (14.7, 15.3)
0.89 1.11
INR
(0.88, 0.90) (1.10, 1.14)
F Other Supportive Instrument Performance Characteristics Data:
Instrument Family Comparison Study
An instrument family comparison study between STA analyzer families was conducted to
validate that there is no significant difference within each family of analyzers; namely, the STA-
R Family and the STA Compact Family. The STA-R family contains STA-R, STA-R Evolution
and STA R Max. The STA Compact family contains STA Compact and STA Compact Max.
Two studies were conducted, one study to compare the STA-R Evolution and STA-R Max and
another to compare the STA Compact and STA Compact Max. Frozen citrated plasma samples
(n=108 for STA-R and STA R Max, n=107 for STA Compact and STA Compact Max) were tested
using one lot of STA - NeoPTimal on STA-R Evolution, STA-R Max, STA Compact and STA
Compact Max. All results met the acceptance criteria and no significant difference for PT in
seconds and INR values was observed within the same family of analyzers.
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.
K211485 - Page 13 of 13

[Table 1 on page 13]
Test (units)		2.5% percentiles		97.5% percentiles
		(95% CI)		(95% CI)
PT (seconds)	11.8
(11.6, 11.9)		14.9
(14.7, 15.3)	
INR	0.89
(0.88, 0.90)		1.11
(1.10, 1.14)	